At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
TG-873870 (Nemonoxacin)drug
Likely dose
TG-873870 (Nemonoxacin) 750 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens
In Brief
A Phase 2 clinical trial evaluating TG-873870 (Nemonoxacin) for Diabetic Foot Infections. Completed, enrolled 40 participants across 16 sites in 4 countries.
Detailed Summary
Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Foot Infections
CountriesSouth Africa, Taiwan, Thailand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJun 2008
Primary CompletionApr 2009
Study CompletionJun 2009
TodayJul 2026
First PostedMay 28, 2008
Enrollment StartJun 1, 2008
Primary CompletionApr 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.1 years ago
Interventions
TG-873870 (Nemonoxacin)drug
750 mg